Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: A Phase I study

H. Y. Sheikh, J. W. Valle, K. Palmer, A. Sjursen, O. Craven, G. Wilson, R. Swindell, M. P. Saunders

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer. Twenty-five patients, median age 63 (range 24-79) years, World Health Organisation performance status 0-2 and median four marker lesions, received irinotecan 180 mgm -2 on day 1, oxaliplatin 85-100 mgm -2 on day 15 and UFT 200-300 mgm -2 day -1 with LV 90 mg day -1, days 1-21 of a 28-day cycle. Patients were treated in cohorts of three. At the highest dose (irinotecan 180 mgm -2, oxaliplatin 100 mgm -2 and UFT 300 mgm -2 day -1), three of four patients experienced grade 3 toxicity. Diarrhoea, lethargy and vomiting were dose-limiting. Three of nine patients had grade 2 toxicities at the maximum tolerated dose (irinotecan 180 mgm -2, oxaliplatin 100 mgm -2 and UFT 250 mgm -2 day -1). There were no grade 3 toxicities in the first month of therapy. The overall response rate was 71% in 21 evaluable patients; progression-free survival was 8.8 months. Alternating irinotecan and oxaliplatin plus UFT is an effective and well-tolerated first-line treatment for patients with advanced colorectal cancer. We recommend a dose of irinotecan 180 mgm -2 on day 1, oxaliplatin 100 mgm -2 on day 15 and UFT 250 mgm -2 day -1 with LV 90 mg day -1 on days 1-21 of a 28-day cycle for future studies. © 2007 Cancer Research UK.
    Original languageEnglish
    Pages (from-to)38-43
    Number of pages5
    JournalBritish Journal of Cancer
    Volume96
    Issue number1
    Publication statusPublished - 15 Jan 2007

    Keywords

    • Advanced colorectal cancer
    • CPT-11
    • Irinotecan
    • Oxaliplatin
    • Tegafur-uracil
    • UFT

    Fingerprint

    Dive into the research topics of 'Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: A Phase I study'. Together they form a unique fingerprint.

    Cite this